这次,徐浩宇不仅打破了扬子江药业半个世纪的“不兼并”惯例,更罕见地将触角伸向了资本市场。作者 | 深水财经社 倪大九成立半个世纪的江苏“隐形药王”扬子江药业有大动作。近日,泰州港股上市公司瑞科生物(02179.HK)发布重磅人事公告,创始人刘勇博士正式辞去董事长及提名委员会主席职务。而接替其董事长位置的,是同处泰州“扬子江药业”的董事长徐浩宇。去年11月,扬子江药业斥资8亿元拿下瑞科生物...
Source Link这次,徐浩宇不仅打破了扬子江药业半个世纪的“不兼并”惯例,更罕见地将触角伸向了资本市场。作者 | 深水财经社 倪大九成立半个世纪的江苏“隐形药王”扬子江药业有大动作。近日,泰州港股上市公司瑞科生物(02179.HK)发布重磅人事公告,创始人刘勇博士正式辞去董事长及提名委员会主席职务。而接替其董事长位置的,是同处泰州“扬子江药业”的董事长徐浩宇。去年11月,扬子江药业斥资8亿元拿下瑞科生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.